Study: AZ, Novartis cancer meds carry heart risks; FDA issues public comment rules;

@FiercePharma: Drugmakers settle healthcare fraud claims‎ for $421M. News | Follow @FiercePharma

> Pfizer's breast-cancer drug Aromasin and similar treatments from AstraZeneca and Novartis make women 26 percent more likely to develop heart disease than an older therapy, a study found. Report

> FDA has set up new rules for people who want to comment during its advisory panel meetings; the guidance outlines how people should request a time to talk and how FDA should respond. FDA release

> Bristol-Myers Squibb's (BMY) cancer drug Sprycel has been given marketing approval in Europe for the treatment of so-called Philadelphia chromosome positive chronic phase chronic myeloid leukemia, or CML. Item

> Abbott Laboratories CEO Miles White was appointed to the board of directors at Caterpillar. Report

> Strike action at AstraZeneca in the U.K. is still suspended in the long-running dispute over pensions. Article

> AstraZeneca has launched an iPhone app to provide UK healthcare professionals with information on genetic tests for lung cancer. Article

> Bayer is aiming to more than double sales in China by 2015 to about €5 billion, or $6.7 billion, with a major chunk of that growth resulting from a €1 billion expansion of polycarbonate production capacity. Story

> Hundreds of people who are to lose their jobs at a pharmaceutical company in Cornwall are to be offered a package of measures to help them find new work. Item

Biotech News

 @FierceBiotech: J&J offers $2.3B in bid for Crucell shares. Article | Follow @FierceBiotech

 @JohnCFierce: Enter the bio-dragon. China taps biotech as one of 7 industries that will grow at 20%+ rate for the next 10 years. News | Follow @JohnCFierce

> WSJ: Big investors pushing Charles River ($CRL) toward the auction block. Item

> Roche spotlights top late-stage drug prospects in pipeline review. Article 

> Teva's oral MS drug clears a PhIII hurdle. News

> NIH to create major new center to speed drug development. Item 

Vaccine News

> Fauci outlines R&D challenges to universal flu vaccine. Article

> PATH $100M meningitis vaccine costs only 50 cents a jab. News

> Bavarian Nordic gets good news on Prostvac. Story

Manufacturing News

> Abbott among top supply chain innovators of all time. Article

> Europe seeks drugs for track/trace trial. Report

> Putin expects big pharma presence in Russia. Item

> Hyderabad Airport joins cold chain age. Report

> Imported death penalty drug to be tested by FDA. News

And Finally... The U.S. Securities and Exchange Commission charged a Maryland business consultant and his uncle with insider trading in Sequenom stock, saying they used codes from the 1987 movie Wall Street to try to hide their scheme. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.